The recent approval of raltegravir granules for suspension in the newborn population offers a new option for the antiretroviral prophylaxis of newborns for the prevention of perinatal transmission. However, there are little data on its use in preterm infants, nor on outcomes following its use as empiric HIV therapy for newborns subsequently found to be infected. We describe here the use of RAL granules for suspension in these cases.
From the *Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
†Université de Montréal, Department of Pediatrics, Montreal, Quebec, Canada
‡CHU Sainte-Justine, Division of Infectious Diseases, Montreal, Quebec, Canada
§CHU Sainte-Justine Research Center, Centre Maternel et Infantile sur le SIDA, Montreal, Canada
¶CHU Sainte Justine, Department of Pharmacy, Montreal, Quebec, Canada
Accepted for publication August 7, 2018.
Supported, in part, by a Fonds de Recherche Santé (FRQS) clinician investigator grant to F.K.
The authors have no conflicts of interest to disclose.
Address for correspondence: Fatima Kakkar, MD, Division of Pediatric Infectious Diseases, CHU Sainte-Justine, 3175 Côte Sainte-Catherine, Montreal, Quebec, Canada. E-mail: firstname.lastname@example.org.